Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation: A Phase II Single Arm Prospective Study

NCT03399669 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03399669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03399669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation: A Phase II Single Arm Prospective Study
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 17, 2015
Completion date
December 31, 2018
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer